News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
605,483 Results
Type
Article (41952)
Company Profile (167)
Press Release (563364)
Multimedia
Podcasts (59)
Webinars (13)
Section
Business (169758)
Career Advice (2467)
Deals (30563)
Drug Delivery (106)
Drug Development (75003)
Employer Resources (151)
FDA (14991)
Job Trends (13535)
News (296391)
Policy (28838)
Tag
Academia (2727)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (88)
Alliances (44083)
ALS (94)
Alzheimer's disease (1425)
Antibody-drug conjugate (ADC) (137)
Approvals (14985)
Artificial intelligence (273)
Autoimmune disease (22)
Automation (16)
Bankruptcy (317)
Best Places to Work (11109)
BIOSECURE Act (16)
Biosimilars (95)
Biotechnology (113)
Bladder cancer (84)
Brain cancer (29)
Breast cancer (276)
Cancer (2272)
Cardiovascular disease (188)
Career advice (2074)
Career pathing (33)
CAR-T (154)
Cell therapy (431)
Cervical cancer (17)
Clinical research (61215)
Collaboration (856)
Company closure (1)
Compensation (334)
Complete response letters (22)
COVID-19 (2538)
CRISPR (44)
C-suite (256)
Cystic fibrosis (88)
Data (2202)
Decentralized trials (2)
Denatured (19)
Depression (51)
Diabetes (268)
Diagnostics (6264)
Digital health (17)
Diversity (4)
Diversity, equity & inclusion (40)
Drug discovery (124)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (94)
Earnings (61925)
Editorial (38)
Employer branding (19)
Employer resources (136)
Events (89063)
Executive appointments (753)
FDA (16238)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (753)
Gene editing (109)
Generative AI (22)
Gene therapy (320)
GLP-1 (727)
Government (4345)
Grass and pollen (5)
Guidances (66)
Healthcare (17930)
Huntington's disease (24)
IgA nephropathy (29)
Immunology and inflammation (130)
Indications (30)
Infectious disease (2687)
Inflammatory bowel disease (137)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (524)
IPO (13940)
IRA (45)
Job creations (2866)
Job search strategy (1700)
Kidney cancer (11)
Labor market (20)
Layoffs (444)
Leadership (24)
Legal (6213)
Liver cancer (75)
Lung cancer (330)
Lymphoma (147)
Machine learning (7)
Management (53)
Manufacturing (298)
MASH (74)
Medical device (12909)
Medtech (12913)
Mergers & acquisitions (17168)
Metabolic disorders (687)
Multiple sclerosis (81)
NASH (23)
Neurodegenerative disease (101)
Neuropsychiatric disorders (31)
Neuroscience (1986)
NextGen: Class of 2025 (6147)
Non-profit (4431)
Now hiring (32)
Obesity (354)
Opinion (225)
Ovarian cancer (73)
Pain (93)
Pancreatic cancer (85)
Parkinson's disease (152)
Partnered (20)
Patents (231)
Patient recruitment (114)
Peanut (46)
People (54501)
Pharmaceutical (48)
Pharmacy benefit managers (10)
Phase I (18911)
Phase II (26944)
Phase III (20456)
Pipeline (1202)
Policy (141)
Postmarket research (2353)
Preclinical (7738)
Press Release (68)
Prostate cancer (106)
Psychedelics (37)
Radiopharmaceuticals (251)
Rare diseases (384)
Real estate (4898)
Recruiting (62)
Regulatory (20373)
Reports (26)
Research institute (2360)
Resumes & cover letters (362)
Rett syndrome (5)
RNA editing (3)
RSV (40)
Schizophrenia (75)
Series A (136)
Series B (84)
Service/supplier (9)
Sickle cell disease (56)
Special edition (10)
Spinal muscular atrophy (146)
Sponsored (29)
Startups (3167)
State (2)
Stomach cancer (14)
Supply chain (66)
Tariffs (37)
The Weekly (38)
Vaccines (657)
Venture capitalists (35)
Weight loss (238)
Women's health (30)
Worklife (17)
Date
Today (126)
Last 7 days (838)
Last 30 days (2486)
Last 365 days (31329)
2025 (10307)
2024 (33645)
2023 (37801)
2022 (48341)
2021 (52281)
2020 (50831)
2019 (44623)
2018 (33801)
2017 (30178)
2016 (28955)
2015 (33673)
2014 (25444)
2013 (20696)
2012 (22231)
2011 (23032)
2010 (20401)
Location
Africa (776)
Alabama (51)
Alaska (7)
Arizona (162)
Arkansas (13)
Asia (36961)
Australia (7241)
California (5514)
Canada (1928)
China (529)
Colorado (251)
Connecticut (256)
Delaware (152)
Europe (84137)
Florida (863)
Georgia (197)
Idaho (51)
Illinois (531)
India (25)
Indiana (311)
Iowa (10)
Japan (160)
Kansas (90)
Kentucky (23)
Louisiana (11)
Maine (61)
Maryland (844)
Massachusetts (4113)
Michigan (217)
Minnesota (359)
Mississippi (1)
Missouri (78)
Montana (25)
Nebraska (23)
Nevada (63)
New Hampshire (67)
New Jersey (1652)
New Mexico (27)
New York (1665)
North Carolina (910)
North Dakota (9)
Northern California (2357)
Ohio (193)
Oklahoma (12)
Oregon (33)
Pennsylvania (1255)
Puerto Rico (13)
Rhode Island (32)
South America (1066)
South Carolina (23)
South Dakota (1)
Southern California (2128)
Tennessee (94)
Texas (838)
United States (21340)
Utah (178)
Virginia (142)
Washington D.C. (59)
Washington State (511)
West Virginia (3)
Wisconsin (63)
605,483 Results for "dariohealth formerly known as labstyle innovations".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Business
DarioHealth Reports First Quarter 2024 Financial and Operating Results
DarioHealth Corp., a leader in the global digital health market, reported financial results for the first quarter 2024.
May 15, 2024
·
26 min read
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
DarioHealth Expands GLP-1 Weight-Loss Solution, Unlocking New Revenue Streams in Rapidly Growing Multi Billion Dollar Market
January 14, 2025
·
2 min read
Business
DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th
DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time.
May 7, 2024
·
2 min read
Business
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
DarioHealth Corp., a leader in the global digital health market, reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
March 28, 2024
·
27 min read
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Business
DarioHealth Reports Third Quarter 2023 Financial and Operating Results
DarioHealth Corp., a leader in the global digital health market, reported financial results for the third quarter 2023 and provided a corporate and commercial update.
November 2, 2023
·
21 min read
Pharm Country
DarioHealth to Host Investor Day on The Rise of Digital Health
DarioHealth Corp., a leader in the global digital health market, announced that it will host an in-person investor day in New York at the offices of Sullivan & Worcester LLP located at 1633 Broadway, 32nd floor, on October 17, 2023 at 11:00 AM ET.
October 3, 2023
·
4 min read
Press Releases
Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
January 7, 2025
·
1 min read
1 of 60,549
Next
